Recent Price Movement and Trading Patterns
Beryl Drugs has experienced a notable fall over the past week, with a one-week return of -4.22%, considerably worse than the Sensex's decline of -1.69%. The stock's year-to-date performance is even more concerning, showing a decline of -9.74% compared to the Sensex's modest fall of -1.87%. Over the last year, the stock has plummeted by -37.16%, starkly contrasting with the Sensex's positive return of 9.56%. This persistent underperformance has been accompanied by erratic trading patterns, including a missed trading day within the last 20 sessions and a recent two-day consecutive fall resulting in a cumulative loss of 7.12%.
On 13-Jan, the stock opened with a gap down of -3.29%, signalling immediate bearish sentiment among investors. Intraday, it touched a low of ₹21.12, with the weighted average price indicating that most trading volume occurred near this low point. This suggests selling pressure dominated throughout the session. Furthermore, Beryl Drugs is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—highlighting a sustained downtrend and weak technical positioning.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Fundamental Challenges Weighing on Investor Confidence
Despite a seemingly attractive valuation indicated by a Return on Capital Employed (ROCE) of 11 and an enterprise value to capital employed ratio of 1.1, the company’s underlying fundamentals raise concerns. Over the past year, profits have declined by 11%, signalling operational challenges. The stock’s long-term fundamental strength is weak, with an average ROCE of just 7.27%, which is modest for the pharmaceutical sector.
Growth metrics also paint a subdued picture. Net sales have grown at an annual rate of 11.44% over the last five years, while operating profit has increased at a slightly lower rate of 10.53%. These figures suggest moderate expansion but not at a pace that excites investors. More critically, the company’s ability to service its debt is poor, with an average EBIT to interest coverage ratio of 0.82, indicating potential financial strain and heightened risk.
The company’s quarterly earnings per share (EPS) have also been disappointing, with the latest quarter reporting a low EPS of ₹0.02. This flat result in September 2025 further dampens investor enthusiasm and contributes to the stock’s negative sentiment.
Market Position and Shareholder Composition
Beryl Drugs is predominantly held by non-institutional shareholders, which may contribute to increased volatility and less stable demand for the stock. The stock’s liquidity is adequate for trading, but recent delivery volumes have surged by 166.3% compared to the five-day average, indicating rising investor participation amid the sell-off. This heightened activity, however, has not translated into price support, as selling pressure remains dominant.
Holding Beryl Drugs from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Comparative Performance and Investor Outlook
When benchmarked against broader market indices and sector peers, Beryl Drugs has consistently underperformed. Over the last three years, the stock has delivered a 34.10% return, lagging behind the Sensex’s 38.78%. The one-year return of -37.16% is particularly stark, underscoring the stock’s struggles in recent times. This underperformance extends to the BSE500 index as well, where the stock has lagged over multiple time frames including one year, three years, and three months.
Given these factors, the stock’s recent decline is a reflection of both weak operational performance and negative market sentiment. Investors appear cautious due to the company’s limited growth prospects, poor debt servicing ability, and disappointing earnings. The technical indicators reinforce this bearish outlook, with the stock trading below all major moving averages and opening sharply lower on 13-Jan.
In summary, Beryl Drugs Ltd’s share price is falling primarily due to its weak long-term fundamentals, disappointing profit trends, and sustained underperformance relative to market benchmarks. While valuation metrics suggest some attractiveness, these are overshadowed by operational challenges and investor concerns about the company’s financial health and growth trajectory.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
